These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


236 related items for PubMed ID: 31077450

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients.
    Axelrod D, Segev DL, Xiao H, Schnitzler MA, Brennan DC, Dharnidharka VR, Orandi BJ, Naik AS, Randall H, Tuttle-Newhall JE, Lentine KL.
    Am J Transplant; 2016 May; 16(5):1465-73. PubMed ID: 26603690
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, Watarai Y, Yoshimura N, Tanabe K, Morozumi K, Shimazu M, IDEC-C2B8 ABO-I KTx Study Group.
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [Abstract] [Full Text] [Related]

  • 13. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
    Opelz G, Morath C, Süsal C, Tran TH, Zeier M, Döhler B.
    Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
    [Abstract] [Full Text] [Related]

  • 14. Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience.
    Okumi M, Kakuta Y, Unagami K, Takagi T, Iizuka J, Inui M, Ishida H, Tanabe K.
    Transl Androl Urol; 2019 Apr; 8(2):126-133. PubMed ID: 31080772
    [Abstract] [Full Text] [Related]

  • 15. Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience.
    Uchida J, Kuwabara N, Machida Y, Iwai T, Naganuma T, Kumada N, Nakatani T.
    Transplant Proc; 2012 Jan; 44(1):204-9. PubMed ID: 22310615
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T.
    Contrib Nephrol; 2009 Jan; 162():61-74. PubMed ID: 19001814
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience.
    Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, Koga S, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K.
    Transplantation; 1998 Jan 27; 65(2):224-8. PubMed ID: 9458019
    [Abstract] [Full Text] [Related]

  • 19. Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption - a retrospective study.
    Speer C, Kälble F, Nusshag C, Pego da Silva L, Schaier M, Becker LE, Klein K, Sommerer C, Beimler J, Leo A, Waldherr R, Mehrabi A, Süsal C, Zeier M, Morath C.
    Transpl Int; 2019 Dec 27; 32(12):1286-1296. PubMed ID: 31322786
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.